A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.

[1]  S. Zeuzem,et al.  Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study , 2022, Journal of Hepatology.

[2]  F. Zoulim,et al.  Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension. , 2022, Journal of hepatology.

[3]  F. Tacke,et al.  Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience , 2022, Journal of Hepatology.

[4]  V. de Lédinghen,et al.  Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort , 2022, Journal of Hepatology.

[5]  F. Zoulim,et al.  Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. , 2021, Journal of hepatology.

[6]  P. Lampertico,et al.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease , 2021, Gut.

[7]  D. Kleiner,et al.  Liver-resident bystander CD8+ T cells contribute to liver disease pathogenesis in chronic hepatitis D virus infection , 2021, Zeitschrift für Gastroenterologie.

[8]  F. Zoulim,et al.  Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. , 2019, Journal of hepatology.

[9]  W. Haefeli,et al.  Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection , 2018 .

[10]  M. Manns,et al.  Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta , 2014, Hepatology.

[11]  M. Manns,et al.  Hepatitis C and D, retroviruses and autoimmune manifestations. , 2001, Journal of autoimmunity.